Kelley J. Moss

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas et al. · The Lancet · 2020 · 237 citations

Vaccination, Vaccine Safety, Pediatrics +5

Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion

Siritorn Butrapet, Thomas Childers, Kelley J. Moss et al. · Virology · 2011 · 55 citations

Virus Structure, Molecular Virology, Biochemistry +9

Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes

Steven M. Erb, Siritorn Butrapet, Kelley J. Moss et al. · Virology · 2010 · 50 citations

Virus Structure, Pathogenesis, Viral Pathogenesis +10

A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate

Lisa A. Jackson, Richard Rupp, Athanasia Papadimitriou et al. · Vaccine · 2018 · 42 citations · Full text

Recombinant raccoon pox vaccine protects mice against lethal plague

Jorge E. Osorio, Tim D. Powell, Rexann S. Frank et al. · Vaccine · 2003 · 38 citations

Vaccination, Vaccine Development, Immunology +4